No Data
No Data
No Data
Insider Purchase: Director at $RNAC (RNAC) Buys 7,962 Shares
Cartesian Therapeutics Insider Bought Shares Worth $366,354, According to a Recent SEC Filing
Promising Developments and Strategic Milestones Drive Buy Rating for Cartesian Therapeutics
Needham Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $41
Express News | Needham Reiterates Buy on Cartesian Therapeutics, Maintains $41 Price Target
Cartesian Therapeutics Highlights Progress, 2025 Strategic Priorities